Loading…
BGP, LLC was cited for marketing "BIOCENCE WS Multi-use Selective Antibacterial/Antiviral Human OTC Drug" as an unapproved new drug intended to mitigate, prevent, treat, diagnose, or cure COVID-19, violating section 505(a) of the FD&C Act. The product was also found to be misbranded under sections 502(a) and (ee) of the FD&C Act, with the company promoting it through their website and social media platforms (Facebook and Instagram) without FDA approval. This enforcement action occurred during the COVID-19 public health emergency, when the FDA was actively monitoring for unauthorized products making disease claims.